These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. Leeds JM; Fenneteau F; Gosselin NH; Mouksassi MS; Kassir N; Marier JF; Chen Y; Grosenbach D; Frimm AE; Honeychurch KM; Chinsangaram J; Tyavanagimatt SR; Hruby DE; Jordan R Antimicrob Agents Chemother; 2013 Mar; 57(3):1136-43. PubMed ID: 23254433 [TBL] [Abstract][Full Text] [Related]
6. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948 [TBL] [Abstract][Full Text] [Related]
7. Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection. Duraffour S; Andrei G; Snoeck R IDrugs; 2010 Mar; 13(3):181-91. PubMed ID: 20191435 [TBL] [Abstract][Full Text] [Related]
8. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Berhanu A; King DS; Mosier S; Jordan R; Jones KF; Hruby DE; Grosenbach DW Antimicrob Agents Chemother; 2009 Dec; 53(12):4999-5009. PubMed ID: 19752270 [TBL] [Abstract][Full Text] [Related]
9. Oral Tecovirimat for the Treatment of Smallpox. Grosenbach DW; Honeychurch K; Rose EA; Chinsangaram J; Frimm A; Maiti B; Lovejoy C; Meara I; Long P; Hruby DE N Engl J Med; 2018 Jul; 379(1):44-53. PubMed ID: 29972742 [TBL] [Abstract][Full Text] [Related]
11. Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. Smith SK; Self J; Weiss S; Carroll D; Braden Z; Regnery RL; Davidson W; Jordan R; Hruby DE; Damon IK J Virol; 2011 Sep; 85(17):9176-87. PubMed ID: 21697474 [TBL] [Abstract][Full Text] [Related]
12. Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques. Russo AT; Grosenbach DW; Brasel TL; Baker RO; Cawthon AG; Reynolds E; Bailey T; Kuehl PJ; Sugita V; Agans K; Hruby DE J Infect Dis; 2018 Sep; 218(9):1490-1499. PubMed ID: 29982575 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Grosenbach DW; Berhanu A; King DS; Mosier S; Jones KF; Jordan RA; Bolken TC; Hruby DE Proc Natl Acad Sci U S A; 2010 Jan; 107(2):838-43. PubMed ID: 20080762 [TBL] [Abstract][Full Text] [Related]
14. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. Stabenow J; Buller RM; Schriewer J; West C; Sagartz JE; Parker S J Virol; 2010 Apr; 84(8):3909-20. PubMed ID: 20130052 [TBL] [Abstract][Full Text] [Related]
15. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Stittelaar KJ; Neyts J; Naesens L; van Amerongen G; van Lavieren RF; Holý A; De Clercq E; Niesters HG; Fries E; Maas C; Mulder PG; van der Zeijst BA; Osterhaus AD Nature; 2006 Feb; 439(7077):745-8. PubMed ID: 16341204 [TBL] [Abstract][Full Text] [Related]
16. In vitro efficacy of ST246 against smallpox and monkeypox. Smith SK; Olson VA; Karem KL; Jordan R; Hruby DE; Damon IK Antimicrob Agents Chemother; 2009 Mar; 53(3):1007-12. PubMed ID: 19075062 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Nalca A; Hatkin JM; Garza NL; Nichols DK; Norris SW; Hruby DE; Jordan R Antiviral Res; 2008 Aug; 79(2):121-7. PubMed ID: 18479761 [TBL] [Abstract][Full Text] [Related]
18. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge. Parker S; D'Angelo J; Buller RM; Smee DF; Lantto J; Nielsen H; Jensen A; Prichard M; George SL Antiviral Res; 2021 Nov; 195():105179. PubMed ID: 34530009 [TBL] [Abstract][Full Text] [Related]
19. Monkeypox treatment: Current evidence and future perspectives. Khani E; Afsharirad B; Entezari-Maleki T J Med Virol; 2023 Jan; 95(1):e28229. PubMed ID: 36253931 [TBL] [Abstract][Full Text] [Related]
20. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus. DeLaurentis CE; Kiser J; Zucker J Antimicrob Agents Chemother; 2022 Dec; 66(12):e0122622. PubMed ID: 36374026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]